Trial Profile

Phase II window of opportunity study of short term preoperative treatment with enzalutamide (alone or in combination with exemestane) in patients with primary breast cancer.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Enzalutamide (Primary) ; Exemestane
Indications Early breast cancer; Triple negative breast cancer
Focus Therapeutic Use
Acronyms ARB
Sponsors Astellas Pharma Europe Ltd

Most Recent Events

05 Jul 2024 Status changed from active, no longer recruiting to completed.
10 Oct 2020 This trial has been discontinued in UK (Global End Date: 31 Mar 2020), according to European Clinical Trial Database record.
24 Feb 2020 Planned End Date changed from 1 Mar 2019 to 1 Mar 2020.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com